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Introduction
The epidermal growth factor (EGF) receptor (EGFR) and its
complex network of protein interactions form one of the most
widely distributed control systems of cell proliferation and
differentiation, and represent a locus that is frequently mutated
in cancer (Carpenter, 1999; Gschwind et al., 2001; Yarden and
Sliwkowski, 2001). The large body of knowledge regarding
EGFR function includes detailed data on the receptor structure,
signaling and trafficking pathways, regulatory mechanisms and
cancer therapy (Carpenter, 1999; Gschwind et al., 2004;
Gschwind et al., 2001; Hackel et al., 1999; Jorissen et al., 2003;
Polo and Di Fiore, 2006; Schlessinger, 2000; Schlessinger,
2002; Wiley, 2003; Yarden and Sliwkowski, 2001). However,
the network of activating stimuli remains incompletely
understood. The EGFR is not only activated by direct binding
of its several ligands (Dong et al., 2005; Yarden and
Sliwkowski, 2001), but also by indirect signals emerging from
G-protein-coupled receptors (GPCRs) (Carpenter, 1999;
Carpenter, 2000; Gschwind et al., 2001; Wetzker and Bohmer,
2003). This opens the possibility that stimuli as ubiquitous as
extracellular nucleotides, such as ATP and ADP, acting through
certain members of the P2Y receptor (P2YR) family constitute
generalized regulators of EGFR function, under both
physiological and pathological conditions.
The EGFR is a transmembrane protein that possesses an
extracellular ligand-binding domain, a transmembrane domain
and an intracellular tyrosine kinase domain (Schlessinger,
2000). Upon ligand binding, the receptor dimerizes and its
intracellular tyrosine kinase domain becomes activated,
resulting in the phosphorylation of several tyrosines on the
receptor tail that serve as recruitment sites for signaling
elements (Schlessinger, 2000; Schlessinger, 2002). Activated
EGFR conveys mitogenic signals mainly through the Ras-Raf-
MEK-MAPK pathway (Marmor et al., 2004; Schlessinger,
2002). An important aspect in the regulation of EGFR function
is the control of receptor activation by the availability of
suitable stimuli (Dong et al., 2005). Different soluble ligands
can bind and activate the EGFR, including the most
characterized EGF, transforming growth factor  (TGF) and
heparin-binding EGF-like growth factor (HB-EGF) (Yarden
and Sliwkowski, 2001). EGFR ligands are synthesized as
integral membrane protein precursors (Massague and
Pandiella, 1993), which, once integrated into the cell surface,
can act as juxtacrine stimuli or as soluble stimuli released by
cell surface metalloproteases (Dong et al., 2005; Dong et al.,
1999; Izumi et al., 1998; Prenzel et al., 1999; Singh et al., 2004;
Yan et al., 2002). The releasing process can be regulated by
signaling elements such as Src, calcium influx and protein
Epidermal growth factor receptor (EGFR) function is
transregulated by a variety of stimuli, including agonists of
certain G-protein-coupled receptors (GPCRs). One of the
most ubiquitous GPCRs is the P2Y1 receptor (P2RY1,
hereafter referred to as P2Y1R) for extracellular
nucleotides, mainly ADP. Here, we show in tumoral HeLa
cells and normal FRT epithelial cells that P2Y1R
broadcasts mitogenic signals by transactivating the EGFR.
The pathway involves PKC, Src and cell surface
metalloproteases. Stimulation of P2Y1R for as little as 15-
60 minutes triggers mitogenesis, mirroring the half-life of
extracellular ADP. Apyrase degradation of extracellular
nucleotides and drug inhibition of P2Y1R, both reduced
basal cell proliferation of HeLa and FRT cells, but not
MDCK cells, which do not express P2Y1R. Thus, cell-
released nucleotides constitute strong mitogenic stimuli,
which act via P2Y1R. Strikingly, MDCK cells ectopically
expressing P2Y1R display a highly proliferative phenotype
that depends on EGFR activity associated with an
increased level of EGFR, thus disclosing a novel aspect of
GPCR-mediated regulation of EGFR function. These
results highlight a role of P2Y1R in EGFR-dependent
epithelial cell proliferation. P2Y1R could potentially
mediate both trophic stimuli of basally released nucleotides
and first-line mitogenic stimulation upon tissue damage. It
could also contribute to carcinogenesis and serve as target
for antitumor therapies.
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kinase C (PKC) (Goishi et al., 1995; Gschwind et al., 2001;
Izumi et al., 1998; Soltoff, 1998; Tsai et al., 1997; Zwick et al.,
1999). This property places the EGFR as a downstream
element in the signaling pathways of a variety of cell-surface
receptors (Carpenter, 1999; Guerrero et al., 2004), most
notably GPCRs coupled to Gi or Gq (Carpenter, 1999; Daub
et al., 1997; Daub et al., 1996; Gschwind et al., 2001; Hackel
et al., 1999; Wetzker and Bohmer, 2003). Abundant evidence
suggests that GPCRs could be important regulators of cell
growth and under certain circumstances can even act as
oncoproteins (Marin and Chen, 2004; Marinissen and Gutkind,
2001; Parnot et al., 2002).
GPCRs of the P2YR family constitute generalized autocrine
and paracrine control systems. To date, eight mammalian
P2YR subtypes (P2Y1,2,4,6 and P2Y11-14) have been cloned and
functionally characterized (von Kugelgen, 2006). Two of them
– P2Y1 and P2Y2 – are widely expressed in a variety of cells
(Janssens et al., 1996; Ralevic and Burnstock, 1998; Rice et
al., 1995). P2YRs are activated by the extracellular nucleotides
ATP, ADP, UTP and UDP, which are produced by all cells.
Several P2YR subtypes are activated by the same nucleotides,
but each receptor subtype displays a unique order of potency
for specific nucleotides. Subsets of P2YR share the signal
transduction pathway involving the Gq protein (P2Y1, P2Y2,
P2Y4, P2Y6 and P2Y11), phospholipase C and intracellular
calcium mobilization, whereas others are Gi-coupled receptors
(P2Y12, P2Y13 and P2Y14) that modulate cAMP levels (Ralevic
and Burnstock, 1998; Schwiebert and Zsembery, 2003; von
Kugelgen, 2006).
Nucleotides are released into the medium in large
quantities upon cell injury. Cells also have mechanisms,
which are as yet incompletely understood, to continuously
transport nucleotides down a steep gradient into the medium,
either constitutively or enhanced by a variety of stress
conditions, including hypoxia and cell swelling (Lazarowski
et al., 2003; Schwiebert and Zsembery, 2003). Owing to
the ubiquitous presence of ectonucleotidases, extracellular
nucleotides have relatively short life spans, and are therefore
specially suited for autocrine and paracrine control (Burrell
et al., 2005).
Recent evidence suggests that extracellular nucleotides can
exert mitogenic roles by activating certain P2YRs. Addition of
ATP to the medium provides synergistic stimuli mediated by
P2Y2R upon growth factor mitogenic effects in both normal
and tumorigenic cells (Erlinge, 1998; Neary et al., 1999;
Schafer et al., 2003; Tornquist et al., 1996; Tu et al., 2000;
Wagstaff et al., 2000; Wang et al., 1992; Yu et al., 1996).
P2Y6R (Schafer et al., 2003) and P2Y12R (Van Kolen et al.,
2006) are also involved in mitogenesis. To date, P2Y2R is the
only receptor subtype to transactivate the EGFR (Liu et al.,
2004; Morris et al., 2004; Schafer et al., 2003; Soltoff et al.,
1998; Wagstaff et al., 2000). The short life span of extracellular
nucleotides raises concern about their actual mitogenic
potential, because proliferative responses can require long
exposure periods to mitogenic stimuli, including EGF (Jones
and Kazlauskas, 2001a; Shechter et al., 1978). Most studies on
cell proliferation have used high-dose, long-term incubation
and repeated application of exogenously added nucleotides.
Thus, it is important to better define the mitogenic potential of
cell-released nucleotides and the contribution of the EGFR to
the effects of other P2YR subtypes.
It is also important to assess the mitogenic role of
extracellular nucleotides in epithelial cells, in which the
EGFR is a crucial regulator of proliferation and
differentiation (Miettinen et al., 1995; Sibilia and Wagner,
1995; Threadgill et al., 1995) and from which most human
cancers derive (Peto, 2001). In epithelial cells, the role of
extracellular nucleotides has been mainly characterized in
short-term responses associated with ion transport, including
airway mucus fluidity, cell volume regulation and ischemic
protection (Leipziger, 2003; Schwiebert and Zsembery,
2003). Mitogenic responses to exogenously added P2YR
agonists have been described in endothelial cells (Erlinge,
1998), but other normal epithelial cells remain largely
unexplored.
Here, we studied the P2RY1 (hereafter referred to as
P2Y1R), which is as ubiquitous as P2Y2R but has different
properties. P2Y1R and P2Y2R share only 31% amino acid
similarity (Sak and Webb, 2002), have different preferences for
nucleotides (von Kugelgen, 2006) and distribute with opposite
polarity in epithelial cells (Wolff et al., 2005). Although P2Y2R
is better activated by ATP and UTP, and resides in the apical
domain of epithelial cells, P2Y1R is more sensitive to ADP,
and is basolaterally distributed in epithelial cells (Wolff et al.,
2005), sharing this polarity with the EGFR (He et al., 2002).
We provide evidence that P2Y1R can mediate mitogenic
signals of endogenously released nucleotides in normal
epithelial cells, Madin-Darby canine kidney (MDCK) and
Fisher rat thyroid (FRT) cells, as well as in tumoral HeLa cells,
by transactivating the EGFR pathway. The results indicate that
nucleotides constitute strong mitogenic signals, even for short
stimulation time periods. Strikingly, we also found that ectopic
expression of P2Y1R in epithelial MDCK cells leads to a state
of increased EGFR-dependent cell proliferation, accompanied
by increased expression of EGFR. These results show a
prominent role of the P2Y1R in the regulation of epithelial cell
proliferation. Abnormalities in the functional relationship
between P2Y1R and the EGFR may contribute to
cancerogenesis.
Results
P2Y1R and EGFR in FRT, MDCK and HeLa cell lines
To study the role of P2Y1R in cell proliferation and its
dependency on EGFR we used normal epithelial FRT and
MDCK cells and epithelial-derived tumoral HeLa cells as
model systems. Immunoblot analysis showed that HeLa cells
and FRT cells have readily detectable expression levels
of both receptors (Fig. 1; lanes 1 and 2). Densitometric
scanning indicated that HeLa cells express higher levels
of P2Y1R (~8.5-fold) and EGFR (~29-fold) compared with
FRT cells. Thus, these cells provide model systems to study
the functional relationships of endogenously expressed
P2Y1R and EGFR in normal and tumoral cell contexts.
Instead, in MDCK cells neither P2Y1R nor EGFR could be
detected under the immunoblot conditions of the other
cells (lane 3). However, the EGFR but not P2Y1R became
apparent by increasing the exposure time (lane 4). Functional
assays further indicated that MDCK cells do not express
P2Y1R (see later). Thus, MDCK cells provide a suitable
model system to study the mitogenic effect of ectopically
expressed P2Y1R in the context of low EGFR expression
levels.











4291P2Y1R stimulates EGFR-mediated mitogenesis
P2Y1R mediates cell proliferation induced by
extracellular nucleotides
Before testing the effects of different P2Y1R agonists on cell
proliferation, we determined the doubling-time periods of
HeLa (18.2±0.7 hours) and FRT (20.3±1.3 hours) cells. With
these results, we performed [3H]thymidine incorporation
assays over 16-18 hours to include almost the total cell cycle.
The cells were previously synchronized by 24 hours of serum
starvation. Under these conditions the P2Y1R synthetic
agonist 2-methylthioadenosine 5-diphosphate (2-MeSADP)
(Fig. 2A) and its natural ligand ADP (Fig. 2B), increased FRT
and HeLa cell proliferation in a concentration-dependent
manner, with similar effective concentration 50 (EC50), in the
range of 25 to 75 nM. Both HeLa and FRT cells also
increased their proliferation rate in response to ATP, but not
UTP, which is a P2Y2R and P2Y4R agonist. UDP, a P2Y6R
agonist, provoked mitogenic effects only in FRT cells (Fig.
2C).
The agonist 2-MeSADP can potentially activate other
nucleotide receptors, such as P2Y12R, P2Y13R and P2X.
Fig. 1. P2Y1R and EGFR
expression in non-tumoral
epithelial FRT and MDCK
cells and in tumoral HeLa
cells. Cell extracts analyzed
by immunoblot and ECL
with polyclonal antibodies
against P2Y1R and the
EGFR show readily
detectable expression levels
of both receptors in HeLa
and FRT cells (lanes 1 and
2) but not in MDCK cells
(lane 3). The EGFR, but not
the P2Y1R, becomes
apparent in MDCK extracts
when the film is exposed for
a longer time (lane 4).
Molecular size markers (in
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Fig. 2. Nucleotides stimulate cell proliferation through P2Y1R. P2Y1R agonists, 2-MeSADP (A) and ADP (B), increase cell proliferation in a
concentration-dependent manner (n=4-8). [3H]thymidine incorporation assays show that HeLa and FRT cells pretreated for 1 hour with
different concentrations of the agonists increase their proliferation rate. The EC50 of the agonists is indicated. (C) [3H]thymidine incorporation
after 1 hour of stimulation with 1 M P2YR agonist. Compared with P2Y1R agonists 2-MeSADP, ATP and ADP, which increase cell
proliferation, the P2Y2R agonist UTP shows no effect. The P2Y6R agonist UDP induces cell proliferation only in FRT cells. Results are
normalized against control cells. Values are the means ± s.e.m. *P<0.05, **P<0.01, Dunnett’s test compared with controls (n=5). (D) Cell
proliferation induced by 1 M 2-MeSADP is selectively mediated by P2Y1R, since it was abrogated by the selective P2Y1R antagonist
MRS2179, which in turn does not affect the proliferative response to 10 M UDP, as shown for FRT cells (n=3-4). Only the carrier culture












However, the P2Y1R-specific antagonist 2-deoxy-N6-
methyladenosine 3, 5-biphosphate (MRS2179) blocked the
2-MeSADP induced cell proliferation in a concentration-
dependent manner (Fig. 2D). As control of specificity,
MRS2179 did not affect the mitogenic effect of UDP (Fig.
2D). Therefore, P2Y1R conveys mitogenic signals in
response to activation by both synthetic agonist and natural
nucleotides.
The mitogenic effect elicited by a 1-hour incubation with
nucleotides was surprising. Cells usually require several hours
of exposure to growth factors, covering two distinct phases of
signaling to orchestrate a proliferative response: one that
triggers entering into G1 and the other to surpass the restriction
point of the cell cycle 7-9 hours later (Jones and Kazlauskas,
2001a; Jones and Kazlauskas, 2001b; Pennock and Wang,
2003; Shechter et al., 1978). Therefore, we assessed the effect
of incubating the cells for 1 hour with different concentrations
of either EGF or fetal bovine serum (FBS). Although FRT cells
responded to EGF in a concentration-dependent manner, HeLa
cells showed no response to a wide range of EGF
concentrations (Fig. 3A). Neither FRT nor HeLa cells
responded to a 1-hour incubation with 10% FBS, but were
rescued from the proliferative arrest by longer incubation
periods, as shown for a 16-hour stimulation (Fig. 3B). These
results illustrate the effectiveness of the nucleotides as
mitogenic signals, suggesting that they trigger a cascade of
events encompassing later processes required for surpassing
the restriction point of the cell cycle.
Cell-released nucleotides constitute P2Y1R-mediated
mitogenic signals
An important unsolved question is whether and to what extent
nucleotides endogenously released by cells regulate basal cell
proliferation rates. We approached this problem by analyzing
the extracellular concentrations of nucleotides and the effects
of both the enzyme apyrase, which degrades cell-released
nucleotides, and the antagonist MRS2179, which selectively
blocks the interaction of released nucleotides with P2Y1R. As
nucleotides are rather transient stimuli, because of their short
half-lives (Lazarowski et al., 2003), we also determined the
time dependency of selective P2Y1R stimulation to evoke
proliferative responses, as well as the lifetime of ATP and ADP
in the media.
Extracellular ATP can be metabolized to ADP and AMP,
which, depending on the presence of externally exposed
nucleotidases, was subsequently transformed to adenosine. In
basal conditions, the media of FRT and HeLa cells showed
similar levels of ATP (30-40 nM). However, the FRT cell
medium showed higher levels of ADP (sixfold) and adenosine
(threefold) (Fig. 4A), whereas AMP was undetectable. At the
concentration of ADP detected in the volume of media
currently used for growing the cells, this nucleotide can
certainly contribute to basal mitogenesis of both cells, because
it is within the EC50 range. The effect on basal proliferation of
apyrase and the P2Y1R antagonist MRS2179 supports this
possibility more directly. Apyrase added to the medium for 1
hour led to complete degradation of ATP and ADP,
accompanied by accumulation of AMP in FRT cells and
adenosine in HeLa cells (Fig. 4B). Under these conditions,
FRT and HeLa cells reduced their basal proliferation rates by
15-25%. Cells incubated with MRS2179 showed a similar
inhibitory effect (Fig. 4C).
We next studied how long P2Y1R needs to be stimulated
in FRT cells to elicit a proliferative response. The result was
striking. An incubation period as short as 10-15 minutes with
2-MeSADP was enough to provoke an increased proliferation
activity, as revealed by both [3H]thymidine incorporation
(Fig. 5A) and induction of cyclin D expression (Fig. 5B).
Maximal proliferative responses occurred after 2 hours of
incubation with 1 M 2-MeSADP, decreasing thereafter.
With such time dependency, cell-released nucleotides do have
a mitogenic role. Furthermore, after cell injury by a cross-
scratch, which disrupted about 15% of the cell monolayer, the
extracellular concentration of ATP and ADP increased
dramatically and rapidly, reaching levels of about 500 nM
within the first minute. The half-life of ATP was about 5-10
minutes and that of ADP extended to about 45-60 minutes
(Fig. 5C) – long enough to exert P2Y1R-mediated mitogenic
effects.
Taken together, these results reveal that endogenously
released nucleotides can act as strong trophic factors. The
evidence also highlights the relevance of ADP, the preferred
ligand of P2Y1R. Endogenous nucleotides are therefore first-
line mitogens during tissue-repair processes.
Journal of Cell Science 120 (24)
Fig. 3. Effect of EGF and FBS on FRT and HeLa cell proliferation.
Serum-arrested cells were incubated with different concentrations of
EGF for 1 hour (A) or with 10% FBS for either 1 hour before, or 16
hours during [3H]thymidine incubation (B). Only FRT cells show a
proliferative response to EGF, indicating concentration dependency.
None of the cells responded to just 1 hour of FBS, contrasting with
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4293P2Y1R stimulates EGFR-mediated mitogenesis
Cell proliferation induced by extracellular nucleotides
requires EGFR transactivation 
The mitogenic effects of other GPCRs require transactivation
of the EGFR through pathways involving Src and cell-surface
metalloproteases (Carpenter, 1999; Daub et al., 1997;
Gschwind et al., 2001; Prenzel et al., 1999; Schafer et al.,
2004). PKC has also been implicated (Soltoff et al., 1998; Tsai
et al., 1997). Immunoblot assessment of tyrosine
phosphorylation measures the activation status of both the
EGFR and the downstream extracellular-regulated kinase
(ERK). Incubation of HeLa and FRT cells for just 5 minutes
with 2-MeSADP (1 or 10 nM) activated the EGFR in a
concentration-dependent manner (Fig. 6A). ERK1/2 also
became activated (Fig. 6B), thus mimicking the effect of EGF.
Inhibition of EGFR tyrosine kinase activity with AG1478 in
FRT cells reduced the mitogenic effect of both 2-MeSADP and
EGF in a concentration-dependent manner, with inhibitory
concentration 50 (IC50) values in the range of 1 to 3 nM (Fig.
7A). Similarly, inhibitors of PKC (Ro 318220), Src (PP2) and
metalloproteases (Ilomastat), all prevented 2-MeSADP-
induced proliferation, as shown for HeLa cells (Fig. 7B). The
AG1478 inhibitor of EGFR tyrosine kinase activity completely
abrogated the ERK1/2 activation induced by 2-MeSADP,
indicating that it was dependent on EGFR transactivation (Fig.
7C).
These results indicate that the mitogenic signals conveyed
by P2Y1R stimulation require transactivation of the EGFR
through pathways involving Src, PKC and metalloprotease-
mediated release of EGFR ligands from the cell surface.
Ectopic expression of P2Y1R leads to increased EGFR-
mediated cell proliferation and higher EGFR expression
As we could not detect P2Y1R by immunoblotting in MDCK
cells (see Fig. 1), we tried the more sensitive method of
measuring nucleotide-induced intracellular Ca2+ changes.
MDCK cells did not respond to the selective P2Y1R agonists
ADP and 2-MeSADP, but did increase their intracellular Ca2+
when stimulated with the P2Y2R agonists ATP and UTP (Fig.
8A). The low agonist efficacy of ATP might be expected
considering that this nucleotide is a poor agonist upon canine
P2Y2R (von Kugelgen, 2006). An action of ATP through ionic
P2X receptors that usually require higher nucleotide
concentrations cannot be discarded.
Because our immunoblot and functional assays rule out
P2Y1R expression in MDCK cells, we used these cells as a
model system to study the effect of ectopically expressed
P2Y1R. This is interesting because gain-of-function
phenotypes can be produced by overexpression of wild-type
GPCRs (Parnot et al., 2002). In addition, ectopic expression of
a particular GPCR in a cell context that normally lacks the
receptor can disrupt cell proliferation control and produce cell
transformation in the presence of the corresponding ligand
(Marin and Chen, 2004).
We transfected MDCK cells permanently and selected
colonies that expressed P2Y1R at similar or even lower levels
than the FRT endogenous receptor (Fig. 8B; lanes 2 and 3).
MDCK cells ectopically expressing P2Y1R showed an
increased viability, reflected by the higher slope and maximal
number of living cells reached in culture (Fig. 9A). These
MDCK P2Y1R cells reduced their doubling time to 13.4±0.4
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Fig. 4. Cell-released nucleotides contribute to basal cell proliferation.
Steady-state concentration of extracellular ATP and its metabolites
measured in the medium of FRT and HeLa cells in control conditions
(A; n=10) and after a 1-hour incubation with 2 U/ml apyrase (B;
n=5). ATP and ADP induce cell proliferation and both become
undetectable after apyrase treatment. (C) Endogenous nucleotides
acting through P2Y1Rs participate in the regulation of basal cell
proliferation (n=5). Basal [3H]thymidine incorporation in FRT and
HeLa cells measured after 16 hours of incubation decreased by about
15-25% in the presence of 1 M MRS2179 (P2Y1R antagonist) or 2
U/ml apyrase. All results were normalized against the control. Values
are the means ± s.e.m. *P<0.05, **P<0.01, Dunnett’s test compared












9A insert). By contrast, MDCK cells stably transfected with
the -opioid receptor, another GPCR, did not show these
differences, indicating a selective effect.
MDCK cells permanently expressing P2Y1R also displayed
a higher proliferation rate than wild-type cells, as indicated by
a twofold increase in [3H]thymidine incorporation (Fig. 9B).
MDCK cells expressed relatively low levels of the EGFR,
compared with HeLa and FRT cells (see Fig. 1). However, the
EGFR kinase inhibitor AG1478 (100 nM) abrogated the high
proliferation rate of MDCK P2Y1R (Fig. 9B). MDCK P2Y1R
cells respond to stimulation with P2Y1R exogenous agonist 2-
MeSADP increasing the [3H]thymidine incorporation (Fig. 9C)
and transactivating the EGFR (Fig. 9D). All these results
suggest that ectopic expression of P2Y1R promotes a highly
proliferative phenotype in MDCK cells through a mechanism
involving transactivation of the EGFR.
Interestingly, the MDCK/P2Y1R cells showed threefold
increased levels of EGFR mass, as detected by immunoblotting
(Fig. 10A) and twofold higher expression of newly synthesized
EGFR, as revealed by immunoprecipitation from metabolically
labeled cells (Fig. 10B). EGFR expression is under the control
of the EGFR itself and PKC activities. Thus, we treated the
cells with EGFR and PKC blockers and found a decreased
EGFR expression (Fig. 10C). These results suggest that ectopic
expression of P2Y1R leads to an increased EGFR expression
through a mechanism involving activation of the EGFR and
PKC.
All the results illustrated in Figures 9 and 10 correspond to
the same MDCK P2Y1R clone. However, the analysis of
several clones of stably transfected MDCK cells showed
similar results. All the clones displayed increased cell
proliferation and EGFR expression with respect to wild-type
cells.
Discussion
We found that P2Y1R activation with extracellular nucleotides
acting upon the EGFR constitutes a mitogenic stimulating
system in normal epithelial and tumoral cells. The evidence
indicates that P2Y1R contributes to maintenance of basal
proliferation rates and has the potential to rapidly initiate
proliferative responses after tissue damage. Because both
extracellular nucleotides and P2Y1R are ubiquitous, they are
probably generalized trophic systems and first-line ‘sentinels’
of proliferative requirements in the tissue-repair processes. In
addition, we found that ectopic expression of P2Y1R promotes
the development of a highly proliferative EGFR-mediated
state, associated with an increased expression level of the
EGFR. Therefore, P2Y1R can modulate the mitogenic function
of the EGFR through pathways leading first to its acute
transactivation and later to a huge increase in its expression
levels and signaling activity. The recognized importance of the
EGFR in tumorigenesis suggests the possibility that
abnormally increased P2Y1R signaling contributes to
carcinogenesis and may serve as a target for antitumor
therapies.
We first showed that the P2Y1R agonists 2-MeSADP and
ADP stimulate proliferation of epithelial FRT cells and
cancerous HeLa cells. Although 2-MeSADP can also activate
Journal of Cell Science 120 (24)
Fig. 5. Congruence between time dependency
of P2Y1R stimulation for cell proliferation
and half-life of injury-released nucleotides.
(A) Stimulation time-period necessary for
P2Y1R-induced cell proliferation. FRT cells
were incubated with 1 M 2-MeSADP for the
indicated time periods and then the ligand
was removed and the cells incubated for 16
hours with [3H]thymidine. The proliferative
response requires a minimal stimulation time
of 10 minutes, reaching a maximum by 120
minutes and decreases thereafter (n=4); (B)
Changes in cyclin D levels detected by
immunoblot. FRT cells were incubated either
with carrier culture medium alone (Control,
C) or with 1 M 2-MeSADP for the indicated
times. Stimulation for as little as 15 minutes
leads to increased levels of cyclin D,
analyzed 16 hours later. The quantification of
three separate assays normalized with respect
to actin is shown in the graph. (C) Half-life of
nucleotides released from wounded cultured
cells. Extracellular ATP and ADP
concentrations show a dramatic increase after
cell injury and then gradually decrease. ADP
maintained higher levels for longer periods –
enough to induce P2Y1R-mediated cell
proliferation (n=4). Values are the means ±
s.e.m. *P<0.05, **P<0.01; Dunnett’s test











4295P2Y1R stimulates EGFR-mediated mitogenesis
the P2Y12R and P2Y13R subtypes, there is no evidence that
these receptors are expressed in epithelial cells and the P2Y1R
specific antagonist MRS2179 totally blocked the 2-MeSADP-
promoted proliferation. Therefore, the proliferative response to
2-MeSADP selectively involves stimulation of P2Y1R. As
described for other GPCRs (Carpenter, 1999; Gschwind et al.,
2001; Wetzker and Bohmer, 2003), the P2Y1R mitogenic
response requires transactivation of the EGFR. The blocking
effects of several inhibitors indicate that P2Y1R-mediated cell
proliferation requires Src, PKC and metalloprotease activities.
This is congruent with the proposed pathway involving the
release of an EGFR ligand, such as HB-EGF or TGF from a
cell-surface precursor (Gschwind et al., 2001). Because P2Y1R
is widely distributed in different cell types, including
endothelium, smooth muscle, neurons, glia and epithelial cells
(Buvinic et al., 2006; Janssens et al., 1996; Ralevic and
Burnstock, 1998; Schwiebert and Zsembery, 2003), our results
reveal one of the most ubiquitous EGFR-mediated control
systems of cell proliferation.
Whether cell-released nucleotides have a functional
significance in cell proliferation remains an unresolved
question. All kinds of cells permanently release nucleotides to
the medium. The extracellular resting concentration of
nucleotides is in the nanomolar range and can increase after
hypoxia or cell injury up to the millimolar range (Lazarowski
et al., 2003). However, ectonucleotidase activity rapidly
degrades ATP consecutively to ADP, AMP and adenosine
(Burrell et al., 2005; Lazarowski et al., 2003; Schwiebert and
Zsembery, 2003). We found basal concentrations of ATP and
ADP in the medium surpassing the EC50 for P2Y1R and
showed that nucleotide degradation by apyrase and P2Y1R
inhibition by the antagonist MRS2179 both decreased the basal
proliferation rate of FRT and HeLa cells. Recently, similar
studies in adult neural stem cells (Mishra et al., 2006) and in
prostate cancer cells (Nandigama et al., 2006) show evidence
of mitogenic potential of cell-released nucleotides, and at least
in neurospheres, mediated by P2Y1R (Mishra et al., 2006). We
also show that upon cell injury, ATP and ADP increased several
fold and then decreased with a half-life of 10-15 minutes and
45-60 minutes, respectively. Finally, we determined that a
period as short as 15 minutes of selective P2Y1R stimulation
can elicit proliferative responses. Therefore, nucleotides
released from cells provide P2Y1R-mediated mitogenic
signals. Under basal conditions, extracellular nucleotides
constitute the most ubiquitous trophic factors, whereas after
cellular injury or other stress situations requiring tissue repair,
they can act as first line of defense mitogens.
The mechanism by which nucleotides are capable of
eliciting mitogenic responses even after short periods of
P2Y1R stimulation remains to be elucidated. To enter into
proliferation, serum-arrested epithelial cells, like other cells,
Fig. 6. Stimulation of the P2Y1R transactivates the EGFR pathway.
(A) 2-MeSADP increases the EGFR tyrosine phosphorylation in a
concentration-dependent manner. Quiescent FRT and HeLa cells
were treated for 5 minutes with either 1 or 10 nM 2-MeSADP or 1
nM EGF, as indicated. The EGFR was then immunoprecipitated,
resolved by SDS-PAGE and immunoblotted with anti-
phosphotyrosine monoclonal antibody 4G10 to detect the tyrosine
phosphorylated EGFR (EGFR-P). After stripping, blotted
membranes were incubated with polyclonal antibody EGFR984 for
total EGFR detection. EGFR-P is clearly more intense than in control
cells (‘C’) without agonist stimulation. (B) 2-MeSADP increases
ERK1/2 activation. Quiescent cells treated for the indicated time
periods either with carrier culture medium alone (Control, ‘C’) or
with 10 nM 2-MeSADP or 1 nM EGF were analyzed for ERK
activation by immunoblot against total ERK or phosphorylated ERK
(ERK-P). Each graph corresponds to quantification of three
independent experiments, normalized with respect to the
corresponding total EGFR or ERK protein in each lane. Values are
the means ± s.e.m. *P<0.05, **P<0.01; Dunnett’s test compared with












usually require long periods of stimulation with growth factors,
or two pulses of stimulation separated by several hours (Jones
and Kazlauskas, 2001a; Jones and Kazlauskas, 2001b;
Pennock and Wang, 2003; Shechter et al., 1978). This is
explained by two different requirements: an initial stimuli-
dependent signaling for driving resting cells into G1, and then
a second stimuli-dependent process, which stabilizes
components responsible for surpassing the restriction point that
takes place 7-9 hours later (Jones and Kazlauskas, 2001a).
Therefore, it is intriguing that a short stimulation (15-60
minutes) with nucleotide was enough to trigger mitogenesis,
even in HeLa cells, in which 1 hour of EGF or serum
stimulation did not result in proliferation. It seems that
nucleotides are initiating a cascade of events that progress
toward surpassing the restriction point of the cell cycle via
unknown mechanisms.
It has been previously described that EGF can induce
proliferation of unsynchronized HeLa cells (Hutchings and
Sato, 1978), as we also observed (results not shown). However,
EGF stimulation for either one (Fig. 3A) or 16 hours (results
not shown) was unable to rescue growth-arrested HeLa cells
and induce their proliferation. It is surprising therefore, that
proliferation induced by nucleotides was completely abrogated
by EGFR inhibitors, indicating its dependence on EGFR
activation. How could this apparently contradictory result be
explained? It is known that P2Y1R signaling involves an
increase in intracellular calcium and PKC activation (Ralevic
and Burnstock, 1998; von Kugelgen, 2006). Our results here
provide evidence that P2Y1R signaling leads to a
transactivation of the EGFR that triggers the ERK pathway.
Therefore, nucleotide stimulation through the P2Y1R could
potentially trigger at least two pathways, including the EGFR
pathway, which are both required for proliferation. Inhibition
of one might be enough to abrogate the proliferative response.
A similar explanation, called the ‘dual-signaling-track’ model
has been proposed for other ERK-dependent processes
activated by certain GPCRs (Wetzker and Bohmer, 2003).
Thus, considering that different signaling events seem to be
required to push cells through the G0 to S interval (Jones and
Kazlauskas, 2001b), nucleotides most probably fulfil this
requirement by including the activation of the EGFR, which
by itself would be insufficient to rescue arrested HeLa cells.
Another possibility is that nucleotide-induced transactivation
of the EGFR involves a different, more mitogenic ligand than
EGF.
The relative contribution of different P2YR subtypes to
EGFR-mediated epithelial cell proliferation is not yet clear.
P2Y2R is the only other P2YR subtype previously described to
mediate cell proliferation by transactivating the EGFR (Liu et
al., 2004; Morris et al., 2004; Schafer et al., 2003; Soltoff et
al., 1998; Wagstaff et al., 2000). P2Y2R is mainly activated by
ATP and UTP. Stimulation with these nucleotides leads to
EGFR activation and an increased proliferation of a variety of
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Fig. 7. Cell proliferation mediated by P2Y1R stimulation involves
EGFR transactivation, PKC, Src and metalloprotease activity.
(A) Induction of cell proliferation mediated by P2Y1R stimulation
requires EGFR activation. The EGFR tyrosine kinase blocker
AG1478 inhibits the proliferation of FRT cells induced by either 1
M 2-MeSADP or 10 nM EGF in a concentration-dependent manner
(n=4). (B) HeLa cells pre-incubated for 30 minutes in the absence or
presence of 1 M of MRS2179 (P2Y1R antagonist), Ro 318220
(non-selective PKC inhibitor), PP2 (Src kinase inhibitor), AG1478
(blocker of EGFR tyrosine-kinase activity) or Ilomastat
(metalloprotease inhibitor), were then stimulated with 1 M 2-
MeSADP for 1 hour in the presence of each inhibitor. Results are
normalized against control cells incubated only with the agonist.
Values are the means ± s.e.m. *P<0.05, **P<0.01; Dunnett’s test
compared with control (n=3-6). (C) ERK1/2 activation in response to
P2Y1R agonist depends on EGFR activity. The EGFR tyrosine
kinase blocker AG1478 (100 nM) completely abrogates ERK1/2
activation induced by 2-MeSADP (10 nM, 5 minutes), in FRT and
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cells, including PC12 cells (Soltoff, 1998), MCF7 breast
cancer cells (Wagstaff et al., 2000), astrocytoma cells
transfected with P2Y2R (Liu et al., 2004), cardiomyocytes
(Morris et al., 2004) and A549 lung cancer cells (Schafer et
al., 2003). However, these studies analyzed neither the effects
of apyrase nor the congruency between the lifetime of P2Y2R
stimuli and proliferation requirements. We discarded the
participation of P2Y2R in the nucleotide-dependent
proliferation of FRT and HeLa cells, since in these cells ATP,
ADP and UDP, but not UTP, had mitogenic effects. Therefore,
even though P2Y1R and P2Y2R are frequently co-expressed in
the same cells, including epithelial cells (Schwiebert and
Fig. 8. P2Y1R ectopically expressed in MDCK
cells lacking this receptor. (A) Measures of
intracellular calcium changes show that MDCK
cells do not respond to P2Y1R agonists (n=6-8).
ATP and UTP, but neither ADP nor 2-MeSADP,
provoke rises in intracellular Ca2+ levels in MDCK
cells, further indicating that these cells do not
express P2Y1R. Data are means ± s.e.m.
(B) MDCK cells permanently transfected to
express the P2Y1R (MDCK/P2Y1R). Cells were
selected for ectopic P2Y1R expression levels lower
than those of the endogenous receptor of FRT cells.
Fig. 9. MDCK cells ectopically
expressing the P2Y1R display lower
doubling times and EGFR-dependent
increased proliferation rates.
(A) Viability curves for wild-type (wt)
MDCK cells, or cells stably
transfected with either the P2Y1R
(MDCK/P2Y1R) or -opioid receptor
(MDCK/-opioid). The number of
cells increases with higher slope and
reaches a higher maximum for
MDCK/P2Y1R cells, whereas cells
expressing ectopic -opioid receptor
behave like wild-type MDCK cells.
MDCK P2Y1R cells also show a
reduced doubling time. Values are the
means ± s.e.m. (n=4-6). (B) Basal
proliferation rate of MDCK P2Y1R is
higher than wild-type cells and
sensitive to 0.1 M AG1478, thus
indicating a dependency on EGFR
activity. In MDCK P2Y1R cells,
inhibition of EGFR activity
significantly decreased the
[3H]thymidine incorporation. Cells
were treated with 100 nM AG1478
during 16 hours of [3H]thymidine
incorporation. Values are the means ±
s.e.m. *P<0.05, **P<0.01; Dunnett’s
test compared with control wild-type
cells (n=6). (C) The selective P2Y1R
agonist 2-MeSADP increases
proliferation of MDCK/P2Y1R cells in
a concentration-dependent manner.
Cells were treated with exogenous 2-
MeSADP for 1 hour before [3H]thymidine incorporation. Values are the means ± s.e.m. **P<0.01; Dunnett’s test compared with untreated cells
(n=3). (D) P2Y1R transactivates the EGFR in MDCK P2Y1R cells. The immunoblot shows an increased EGFR tyrosine phosphorylation in
cells treated with either 10 nM 2-MeSADP or 1 nM EGF for 5 minutes, quantified with respect to total EGFR mass and depicted below each












Zsembery, 2003), their simultaneous stimulation is
unnecessary for eliciting a nucleotide-mediated proliferative
response, although both can increase the final outcome (Mishra
et al., 2006). In FRT cells, the mitogenic effect of UDP, which
also requires EGFR kinase activity (not shown), was not
inhibited by MRS2179 and, therefore, compromises another
P2YR subtype distinct from P2Y1R, very likely P2Y6R.
MDCK cells that do not express P2Y1R, responded to ATP and
UTP increasing their intracellular calcium concentration, thus
suggesting that they do express the P2Y2R. However, apyrase
did not decrease their proliferation rate, indicating that P2Y2R
does not contribute to basal mitogenesis in these cells. These
results and the longer half-life of extracellular ADP than ATP
point to P2Y1R as a predominant contributor to epithelial cell
proliferation under physiological conditions.
There is evidence suggesting that GPCRs can act as
oncoproteins (Li et al., 2005; Marin and Chen, 2004;
Marinissen and Gutkind, 2001; Parnot et al., 2002). GPCRs
with activating mutations have been detected in several human
cancerous tumors (Dhanasekaran et al., 1998; Marinissen and
Gutkind, 2001). Interestingly, the ectopic expression or
overexpression of wild-type GPCRs, such as the serotonin 1C
(Julius et al., 1989), muscarinic acetylcholine (Gutkind et al.,
1991), thrombin (Whitehead et al., 1995) and glutamate
receptor 1 (Pollock et al., 2003) receptors, can transform cells
in the presence of their respective ligands. Several
neuropeptides acting through their cognate GPCRs promote
cell proliferation and transformation (Cardona et al., 1991;
Cuttitta et al., 1985; Gutkind, 1998; Heasley, 2001), indicating
that GPCRs can also mediate growth-stimulatory autocrine
loops. We could not find any evidence of P2Y1R expression in
MDCK cells, neither by immunodetection nor by functional
assays, such as nucleotide-induced proliferation or rise in
intracellular Ca2+. Therefore, we used these cells to study the
effects of ectopic expression of P2Y1R. Permanently
transfected epithelial MDCK cells ectopically expressing
P2Y1R (MDCK P2Y1R), even at lower levels than the
endogenous receptor in FRT cells, acquire a highly
proliferative phenotype, manifested under basal conditions and
crucially dependent on EGFR tyrosine-kinase activity.
Unexpectedly, MDCK P2Y1R cells display an increased
expression level of EGFR. To our knowledge, a similar
phenomenon has not been previously described for any other
GPCR. The ectopically expressed P2Y1R probably establishes
an autocrine stimulatory loop fed by endogenously released
nucleotides, leading to increased signaling and
transmodulation of the EGFR. The endogenous expression of
the EGFR is known to increase because of activation of the
PKC and the EGFR itself (Bjorge and Kudlow, 1987; Bjorge
et al., 1989; Earp et al., 1988). Both PKC (Ralevic and
Burnstock, 1998) and the EGFR (this work) participate in the
P2Y1R-signaling pathway. We demonstrated here that
blockade of any of these proteins reduced the expression of
EGFR in MDCK/P2Y1R cells. Thus, besides the role of P2Y1R
in mediating the acute nucleotide transactivation of the EGFR,
P2Y1R seems also to participate in the regulation of EGFR
expression, through a mechanism involving PKC and EGFR
activity. Indeed, these two P2Y1R roles have important
implications for EGFR function in development and
carcinogenesis.
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Fig. 10. MDCK P21R (MDCK/P21R) cells display increased expression levels of the endogenous EGFR. (A) Ectopic expression of P2Y1R
increases EGFR levels. Immunoblots of total cell extracts, densitometrically quantified in four independent experiments and normalized with
respect to actin show a threefold increased level of EGFR in MDCK P2Y1R cells. (B) Ectopic expression of P2Y1R increases EGFR
biosynthesis. Newly synthesized EGFR was immunoprecipitated from cells metabolically labeled for 2 hours with [35S]Met/Cys (200 Ci/ml).
Graph shows twofold increase in synthesis in MDCK P2Y1R cells (n=3). For A and B, values are the means ± s.e.m. ***P<0.001; paired t-test
compared with wild-type cells. (C) Increased EGFR expression in MDCK P2Y1R cells depends on EGFR and PKC activity. Cells were treated
with either 100 nM AG1478 or 10 nM Ro318220 for 6-18 hours before and during the metabolic labeling. Graph show the densitometric
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Most human cancers derive from epithelia (Peto, 2001), and
the proliferation and differentiation of epithelial cells are
crucially dependent on the EGFR (Arteaga, 2002; Miettinen et
al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995;
Yarden, 2001). The EGFR plays fundamental roles in
carcinogenesis. EGFR overexpression or activating mutations
as well as over activity of other elements of the EGFR
signaling pathway are common abnormalities in tumoral
processes (Yarden, 2001). Our results disclose a novel
mechanism by which abnormalities in a GPCR function could
potentially contribute to cancer by promoting a proliferative
phenotype that is highly dependent upon EGFR activity and
increased EGFR expression. P2Y1R could potentially mediate
altered mitogenic responses to environmental nucleotides.
Exaggerated release of nucleotides is expected to occur with
injuries such as chronic inflammation – a condition associated
with cancer (Coussens and Werb, 2002). Anomalies in P2Y1R
leading to its ectopic expression, overexpression or constitutive
activation could promote highly proliferative phenotypes as
suggested by our observations in MDCK P2Y1R cells. This
may also extend to other GPCRs.
Because EGFR function is crucial in processes of cell
differentiation, migration and apoptosis, and the EGFR is also
an effective target for novel antitumor drugs (Gschwind et al.,
2004), we envision a broad range of regulatory roles for
extracellular nucleotides and P2Y1R that remain to be explored.
Materials and Methods
Reagents
DMEM containing high glucose, protein-A-Sepharose, butyric acid, 2-MeSADP,
ADP, ATP, UDP, UTP, Apyrase from potato and MRS2179 were purchased from
Sigma. Fetal bovine serum (FBS) was purchased from Hyclone Laboratories
(Logan, UT). All other cell-culture reagents were from Invitrogen (Carlsbad, CA).
[3H]thymidine and the enhanced chemiluminescence (ECL) system were from
Amersham (Piscataway, NJ). Ro318220, PP2 and AG1478 were purchased from
Calbiochem (La Jolla, CA). Ilomastat was from Chemicon (Temecula, CA). Human
recombinant EGF produced by Chiron (Emeryville, CA) was kindly provided by
Pablo Valenzuela and Carlos George-Nascimento (Austral Biologicals, San Ramon,
CA).
Plasmids and antibodies
The human P2Y1R cDNA (GenBank Acc. no. NM_002563) tagged at the N-
terminus with a HA epitope (HA-P2Y1R) (Wolff et al., 2005), was extracted from
the plasmid pLXSN and subcloned between the EcoRI and XhoI restriction sites
of the pDCNA3 expression vector (Invitrogen). Antibodies EGFR984 and
EGFR1176 were raised in rabbits by injecting the described immunogenic
peptides 984DDVVDADEYLIPQ996 and 1176VAPQSSEFIGA1186 of the EGFR
cytosolic tail (Kris et al., 1985; Margolis et al., 1990), coupled to mollusc C.
concholepas hemocyanin (Blue Carrier, from Biosonda Biothechnology, Santiago,
Chile). The EGFR984 antibody has been previously characterized (Salazar and
Gonzalez, 2002). Polyclonal antibodies against human P2Y1R were similarly
obtained with the C-terminal immunogenic peptide CPEFKQNGDTSL (Moore et
al., 2000). Hybridomas producing monoclonal anti-EGFR antibodies HB8506
reacting with the extracellular domain of the EGFR were from American Type
Culture Collection (Manassas, VA). Anti-phosphotyrosine 4G10 monoclonal
antibody was a gift from María Rosa Bono (Universidad de Chile, Santiago,
Chile). IgG fraction was purified using the Econo-Pac Serum IgG purification kit
(Bio-Rad). Anti-phospho ERK and anti-total ERK were from Sigma, anti-actin
was from abCam (Cambridge, UK) and anti-cyclin D from BD Pharmingen
(Franklin Lakes, NJ).
Cell culture and transfections
Cells were cultured in DMEM (HeLa and MDCK) or F12 (FRT) media
supplemented with 7.5% FBS and antibiotics (100 U/ml penicillin, 100 g/ml
streptomycin and 0.25 g/ml fungizone), maintained at 37°C in a humidified
atmosphere (95% air, 5% CO2) and passaged every 3-4 days. Before the assays,
cells were maintained in serum-free medium for 24 hours. MDCK cells were
transfected with HA-P2Y1R using the Lipofectamine 2000 method and subjected
to selection in 0.8 mg/ml geneticin sulfate (G418) to obtain stable transfectants, then
maintained in 0.4 mg/ml G418.
Immunoblotting and immunoprecipitation
For immunoblot assays, 60 g protein from total cell extracts prepared as described
(Salazar and Gonzalez, 2002) were resolved on 8-10% polyacrylamide SDS gels
and transferred onto nitrocellulose (Schleicher and Schuell, Germany). Proteins
recognized by the primary antibodies anti-P2Y1R (10 g/ml), EGFR984 (1:500),
4G10 (1:1000), anti-actin (1:5000), anti-cyclinD (1 g/ml), anti-phospho ERK
(1:1000) and anti-total ERK (1:1000) were detected using the ECL system and
horseradish peroxidase conjugated anti-rabbit (1:5000) or anti-mouse (1:5000) IgGs
as secondary antibodies. The EGFR was immunoprecipitated with the monoclonal
antibody HB8506 in HeLa cells and with EGFR1176 antibodies in FRT cells,
resolved by SDS-PAGE and immunoblotted with anti-phosphotyrosine monoclonal
antibody 4G10, as described (Salazar and Gonzalez, 2002). For total EGFR
detection, membranes were stripped and incubated with the polyclonal antibody
EGFR984 (Salazar and Gonzalez, 2002).
To assess the biosynthetic levels of EGFR in MDCK cells, cells were first
incubated in Met/Cys-free DMEM (Gibco) and 1% FBS for 30 minutes at 37°C and
then metabolically labeled with 200 Ci/ml [35S] Met/Cys (Perkin Elmer) for 2
hours at 37°C. EGFR was immunoprecipitated with EGFR1176 antibody, resolved
by SDS-PAGE and visualized by fluorography as described (Bravo-Zehnder et al.,
2000; Salazar and Gonzalez, 2002) using Amplify (Amersham). To assess the
dependency of EGFR expression on EGFR and PKC activity, cells were treated with
either 100 nM AG1478 or 10 nM Ro 318220 for 6 or 18 hours before and during
metabolic labelling.
The relevant bands on immunoblots and gels were digitized, and their relative
intensities estimated with NIH or Image J software. In the immunoblots, we used
actin, unphosphorylated EGFR or unphosphorylated ERK as loading reference to
standardize the densitometric intensity. In immunoprecipitation assays of
metabolically labeled EGFR, an aliquot of total cell extracts was precipitated with
20% trichloroacetic acid and counted by liquid scintillation, to discard alterations
in total [35S]Met/Cys incorporation.
[3H]thymidine incorporation assays
FRT or HeLa cells (2.5103 cell/well) seeded in 48-well plates and maintained for
24 hours in medium plus 7.5% FBS, were serum-starved for 24 hours to induce
quiescence. This lowered by 60% the basal [3H]thymidine incorporation in a
reversible manner. After incubation with different stimuli (nucleotides, EGF or FBS)
in the indicated conditions of each experiment, the medium was removed and the cells
were then incubated with 2 Ci /ml [3H]thymidine for 16 hours at 37°C, washed three
times with 1 ml ice-cold PBS and incubated for 20 minutes with 5% trichloroacetic
acid at room temperature. Then, cells were washed twice with ice-cold ethanol,
extracted with 0.5 M NaOH for 30 minutes at 37°C, neutralized with 0.5 M HCl and
[3H]thymidine incorporation was assessed by liquid scintillation. Incubations with
antagonists were made 30 minutes before and during agonist treatment. To assess the
effect of AG1478, apyrase or MRS2179 upon basal proliferation rate, the drugs were
maintained during the 16 hour [3H]thymidine incorporation period.
Viability assays and doubling time calculation
Population doubling time of the cell lines was determined by seeding 5000
cells/well in 24-well plates. Cells were trypsinized every 24 hours and counted using
a hemocytometer. Viability was assessed based on Trypan Blue exclusion. Doubling
time was calculated from the graph of viable cell number versus time (linear zone),
using the formula: doubling time=(ln 2  t)/(ln X/Xo), where X corresponds to the
cell number at time t and Xo corresponds to the initial cell number.
Extracellular nucleotide measurement
FRT and HeLa cells seeded in 24-well tissue-culture plates (40,000 cells/well) and
grown for 72 hours in media supplemented with 7.5% FBS, were placed in 200 l
of Tyrode buffer 4 hours before the nucleotide assay. ATP, ADP, AMP and adenosine
concentrations in the media were assessed at steady state (basal conditions) or after
cell injury provoked by a cross scratch made with a 1 mm tip. The media were
collected and extracellular nucleotides were derivatized for sensitive quantification
of adenyl purines as fluorescent 1, N6-etheno species, by adding 100 l buffer
phosphate-citrate (pH 4) and 10 l chloro-acetaldehyde and then heating for 40
minutes at 80°C, as described (Lazarowski et al., 2004; Todorov et al., 1996). The
reaction was stopped by incubation on ice for 5 minutes. After 24 hours at 4°C, an
automated Merck/Hitachi HPLC apparatus equipped with a fluorescence detector
was used for the identification and quantification of ethenylated species, at
excitation and emission wavelengths of 260 nM and 410 nM, respectively. Each
sample (100 l) was injected into a Lichrocart 125-4 column equilibrated with the
mobile phase (100 mM KH2PO4, 5 mM tetrabutylammonium, 4% acetonitrile, pH
3) at 1 ml/minute. Data from test samples were compared against known
concentrations of derivatized adenosine, AMP, ADP and ATP analyzed in parallel.
Typical elution times of these etheno standards were 1.7 minutes for -adenosine,
1.9 minutes for -AMP, 3.3 minutes for -ADP and 8.2 minutes for -ATP.
Calcium measurements
The rise in intracellular Ca2+ induced by nucleotide agonists was measured in wild-












of 30,000 cells/well in 96-well plates, were grown for 24 hours and incubated with
2.5 M Fluo-3-AM (Molecular Probes) for 1 hour at 37°C. Intracellular Ca2+ levels
were monitored as changes in fluorescence intensity using a fluorescent light
imaging plate reader (FLIPR, Molecular Devices). The peak fluorescence achieved
by each nucleotide concentration was used to plot the concentration-response curve
using GraphPad Prism version 3.00 for Windows (Graph Pad Software, San Diego,
CA). Nucleotides (0.1 nM to 100 M) were applied for 3 minutes, fluorescence
was continually recorded a minute before and during nucleotide addition. The
maximal fluorescence attained with the largest ligand concentration was used to
normalize the curves. Each protocol was performed in duplicate and repeated in
three to four batches of cells.
Statistical analysis
Values were expressed as the mean ± s.e.m. Dunnett’s tables were used to compare
several treatments against the same control and analysis of variance, or paired t-test
was applied when necessary. Curves were plotted using GraphPad Prism version
3.00 for Windows (Graph Pad Software, San Diego, CA). The number of
experiments is indicated by n in each figure.
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